{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:44:06Z","timestamp":1787316246257,"version":"build-2736575974"},"reference-count":20,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"MRFF Accelerated Research Funding Program"},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"crossref","award":["RARUR000103"],"award-info":[{"award-number":["RARUR000103"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001067","name":"JDRF Australia","doi-asserted-by":"crossref","award":["2-SRA-2022"],"award-info":[{"award-number":["2-SRA-2022"]}],"id":[{"id":"10.13039\/501100001067","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001067","name":"JDRF Australia","doi-asserted-by":"crossref","award":["4-SRA-2022-1246-M-N"],"award-info":[{"award-number":["4-SRA-2022-1246-M-N"]}],"id":[{"id":"10.13039\/501100001067","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Approval of teplizumab as disease-modifying therapy for type 1 diabetes heralds a new therapeutic era. To facilitate prevention trials, we determined if the M120 risk score could enrich for type 1 diabetes risk and define early treatment effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>M120, based on age, sex, BMI, IA-2 antibody status, HbA1c, blood glucose, and C-peptide 120 min after oral glucose, was determined in TrialNet participants with multiple islet autoantibodies and those who joined the teplizumab prevention trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Compared with the oral glucose tolerance test, M120 identified 26% more children at high risk of progression. When applied to data from the teplizumab trial, M120 improved after teplizumab (P = 0.0362) and deteriorated after placebo (P = 0.0489) to reveal a significant treatment effect after 6 months (P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>M120 improves risk stratification and identifies early effects of immunotherapy. It could be applied to increase prevention trial efficiency and guide treatment decisions in the clinic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc24-2794","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:07:51Z","timestamp":1744286871000},"page":"1352-1355","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":4,"title":["M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-term Response to Preventive Immunotherapy"],"prefix":"10.2337","volume":"48","author":[{"given":"Minh V.","family":"Le,","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital 1 , Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard C.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Coeliac Research Laboratory, Walter and Eliza Hall Institute of Medical Research 2 , Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[{"name":"Clinical Translation, Walter and Eliza Hall Institute of Medical Research 3 , Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5197-3529","authenticated-orcid":false,"given":"John M.","family":"Wentworth","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital 1 , Parkville, Victoria, Australia"},{"name":"Coeliac Research Laboratory, Walter and Eliza Hall Institute of Medical Research 2 , Parkville, Victoria, Australia"},{"name":"Department of Medicine, Royal Melbourne Hospital 4 , Parkville, Victoria, Australia"},{"name":"St Vincent\u2019s Institute of Medical Research 5 , Fitzroy, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"2026061714330727000_B1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41574-023-00849-w","article-title":"Approval of teplizumab: implications for patients","volume":"19","author":"Speake","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2026061714330727000_B2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061714330727000_B3","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/dc18-0494","article-title":"Low-dose anti-thymocyte globulin (ATG) preserves \u03b2-cell function and improves HbA1c in new-onset type 1 diabetes","volume":"41","author":"Haller","year":"2018","journal-title":"Diabetes Care"},{"key":"2026061714330727000_B4","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and beta-cell function in youth with new-onset type 1 diabetes","volume":"383","author":"Quattrin","year":"2020","journal-title":"N Engl J Med"},{"key":"2026061714330727000_B5","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes","volume":"389","author":"Waibel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061714330727000_B6","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"2026061714330727000_B7","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00125-022-05780-9","article-title":"Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening","volume":"65","author":"Weiss","year":"2022","journal-title":"Diabetologia"},{"key":"2026061714330727000_B8","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1007\/s00125-021-05523-2","article-title":"Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample","volume":"64","author":"Bediaga","year":"2021","journal-title":"Diabetologia"},{"key":"2026061714330727000_B9","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2337\/dc11-0641","article-title":"Validation of the Diabetes Prevention Trial-Type 1 risk score in the TrialNet Natural History Study","volume":"34","author":"Sosenko","year":"2011","journal-title":"Diabetes Care"},{"key":"2026061714330727000_B10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2337\/dc14-1813","article-title":"A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history","volume":"38","author":"Sosenko","year":"2015","journal-title":"Diabetes Care"},{"key":"2026061714330727000_B11","doi-asserted-by":"crossref","first-page":"eabc8980","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026061714330727000_B12","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.2337\/db21-0519","article-title":"The deterrence of rapid metabolic decline within 3 months after teplizumab treatment in individuals at high risk for type 1 diabetes","volume":"70","author":"Sims","year":"2021","journal-title":"Diabetes"},{"key":"2026061714330727000_B13","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00125-017-4384-2","article-title":"Understanding and preventing type 1 diabetes through the unique working model of TrialNet","volume":"60","author":"Battaglia","year":"2017","journal-title":"Diabetologia"},{"key":"2026061714330727000_B14","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.2337\/dc19-2288","article-title":"C-peptide levels in subjects followed longitudinally before and after type 1 diabetes diagnosis in TrialNet","volume":"43","author":"Bogun","year":"2020","journal-title":"Diabetes Care"},{"key":"2026061714330727000_B15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5694\/j.1326-5377.2010.tb03478.x","article-title":"AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures","volume":"192","author":"Chen","year":"2010","journal-title":"Med J Aust"},{"key":"2026061714330727000_B16","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1210\/jc.2017-01490","article-title":"The role of age and excess body mass index in progression to type 1 diabetes in at-risk adults","volume":"102","author":"Ferrara","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061714330727000_B17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00125-004-1507-3","article-title":"Insulin resistance is a risk factor for progression to type 1 diabetes","volume":"47","author":"Fourlanos","year":"2004","journal-title":"Diabetologia"},{"key":"2026061714330727000_B18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41574-020-0381-5","article-title":"Diet and exercise in the prevention and treatment of type 2 diabetes mellitus","volume":"16","author":"Magkos","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026061714330727000_B19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2026061714330727000_B20","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.2337\/dc21-1785","article-title":"Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program","volume":"45","author":"Perreault","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/8\/1352\/803039\/dc242794.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/8\/1352\/803039\/dc242794.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:33:16Z","timestamp":1781721196000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/8\/1352\/158100\/M120-Risk-Score-Improves-Identification-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4,10]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc24-2794","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}